Designed for women diagnosed with breast cancer
WEDNESDAY, Dec. 9, 2015 (HealthDay News) — The Dignitana DigniCap Cooling System cap has been approved by the U.S. Food and Drug Administration to help prevent hair loss in women undergoing chemotherapy for breast cancer.
A computer-controlled system circulates cooled liquid to the cap during chemotherapy. This is designed to constrict blood vessels in the scalp, limiting the amount of chemotherapy drugs that reach the hair follicles, the agency said in a news release.
In clinical testing, more than two-thirds of women who wore the cap reported losing less than half of their hair. And the likelihood of chemotherapy drugs missing an isolated cluster of breast cancer cells in the scalp because of the cap was “extremely rare,” the FDA said. The most common side effects of the cap included headache, neck and shoulder pain, chills, and pain associated with wearing the cap for extended periods.
But since the cap doesn’t work with all chemotherapy drugs, any woman interested in using the product should speak with her doctor, the FDA advised.
The product is produced by Dignitana Inc., based in Lund, Sweden.
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer 
AMH Predicts Benefit of Chemo + Endocrine Therapy in Under 55s With Breast Cancer 
Study IDs Gaps in Hereditary Breast Cancer Risk Assessment Before Gender-Affirming Mastectomy 
Family History Drives Cancer Risk in BRCA Test Groups 
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings 
Genomic Newborn Screening Could ID Cancer Predisposition Syndrome 
Subclinical Cardiac Dysfunction Linked to Neurodegeneration in APOE-ε4 Carriers 
Study IDs Dementia Risk Factors in Those Older Than 90 Years 
